Characterization of CPH:SA microparticle-based delivery of interleukin-1 alpha for cancer immunotherapy.
M M HasibuzzamanRui HeIshrat Nourin KhanRasna SabharwalAliasger K SalemAndrean Llewela Simons-BurnettPublished in: Bioengineering & translational medicine (2022)
CPH:SA-based IL-1α-MPs generated a slow and sustained systemic release of IL-1α resulting in reduced weight loss, systemic inflammation, and hypotension accompanied by an adequate anti-tumor immune response in HNSCC-tumor bearing mice. Therefore, MPs based on CPH:SA formulations may be promising as delivery vehicles for IL-1α to achieve safe, effective, and durable antitumor responses for HNSCC patients.